health-systemsPRODUCT news

APRIL 01, 2007

Mycamine (micafungin sodium)

Astellas Pharma US Inc (Deerfield, Ill) recently launched Mycamine for injection in a 100-mg/vial format. The FDA approved Mycamine in 2005 for the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. The product was previously available only in a 50-mg vial. Mycamine is a member of a new class of antifungal agents, the echinocandins. The product inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Mycamine can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus. Mycamine should be administered by intravenous infusion over the period of 1 hour. More rapid infusions may result in more frequent histamine-mediated reactions. For more information, call 800-727-7003, or visit

Penetrex Self-Sealing Press-In Closures

Andwin Scientific's (Addison, Ill; a division of the Andwin Corp), Penetrex Self-Sealing Press-In Closures ensure safer and more accurate dosing of oral medications. The patented self-sealing design prevents spills and provides an additional layer of child safety for use with child-resistant caps. The flexible seal allows the oral syringe to get to the last drop of medication while the syringe is outside the bottle for a clear view of dosage markings. Extra protection from evaporation and contamination are also provided by the product. The closure fits securely on most bottles in the stated identification (ID) range while allowing the bottle's original child-resistant screw cap to fit over the product. The closures' self-sealing septum allows access to the container's contents using nearly any brand oral syringe. It works by inserting the syringe tip into the closure's seal, turning the bottle upside down, aspirating a measured volume, turning the bottle right-side up, and removing the syringe. The closure instantly recloses, providing a safe and clean seal. Supplied as prepunched, nonsterile, single-use-only 100-count boxes, Penetrex Self- Sealing Press-In Closures are available in the ID range of 15.50 to 18.25 mm. For more information, call 800-297-1220, or visit

Sharps Disposal Containers

EPS Inc (Ivyland, Pa) has expanded its line to include an assorted variety of Sharps Disposal Containers. Manufactured from durable, autoclavable polypropylene, the containers were designed for the safe disposal of needles and blood products. Sharps Disposal Containers are puncture-resistant and are available in 3 styles?designed for phlebotomy trays and carts, in-room use systems, and general transportable needs. All were constructed to allow easy disposal of sharp products without allowing access to the container's contents. The product can be used throughout a medical facility or can accompany emergency medical services personnel in the field. For more information, visit, or call 800-523-8966.

Velcade (bortezomib) for Injection

Millennium Pharmaceuticals Inc (Cambridge,Mass) recently received FDA approval for Velcade for Injection for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy. The approval marks the first indication for the product for lymphoma and the first therapy to receive FDA approval in this treatment setting. Velcade for Injection is also indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. The recommended dose for Velcade for Injection is a 1.3-mg/m2 dose administered as a 3-to 5-second bolus intravenous injection twice weekly for 2 weeks (days 1, 4, 8, and 11), followed by a 10-day rest period (days 12-21). For extended therapy of >8 cycles, the product may be administered on the standard schedule or on a maintenance schedule of once weekly for 4 weeks (days 1, 8, 15, and 22), followed by a 13-day rest period (days 23-35). Velcade for Injection is supplied as individually cartoned 10-mL vials containing 3.5 mg of bortezomib as a white to off-white cake or powder. For more information, visit